Ibandronic acid/pamidronic acid/zoledronic acid
- PDF / 170,439 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 83 Downloads / 216 Views
1
S
Osteonecrosis of the jaw and hypocalcaemia: 3 case reports In a retrospective study of 181 patients, who were enrolled from 1 January 2005 to 31 May 2009, three patients including a 52-year-old woman [not all ages not sexes stated] were described, who developed osteonecrosis of the jaw (one patient) and hypocalcaemia (two patients) during treatment with ibandronic acid, pamidronic acid or zoledronic acid [not all outcomes stated]. Patient 1: A 52-year-old woman, who had breast cancer with bone metastases, started receiving IV infusions of zoledronic acid [zoledronate] 4mg over 15 min every 4 weeks along with unspecified anticancer therapy. After 27 months of zoledronic acid therapy, she developed osteonecrosis of the jaw. She was treated with docetaxel [docetaxol] plus capecitabine for six cycles, followed by unspecified aromatase inhibitors for 23 months. She received ibandronic acid [ibandronate] following the occurrence of osteonecrosis of the jaw. She had a history of periodontal diseases and had undergone a dentoalveolar procedure only a few months prior to the onset of osteonecrosis of the jaw. This complication required surgical removal of necrotic bone, and microscopic examination showed necrotic bone along with micotic debris. She was alive and receiving treatment with ibandronic acid and fulvestrant. Patient 2: The patient, who had breast cancer with bone metastases, started receiving IV infusions of ibandronic acid [ibandronate] 4mg over 2h every 4 weeks along with unspecified anticancer therapy. Twenty-one months following ibandronic acid therapy, the patient was hospitalised with hypocalcaemia. Patient 3: The patient, who had breast cancer with bone metastases, started receiving IV infusions pamidronic acid [pamidronate] 90mg over 4h every 4 weeks along with unspecified anticancer therapy. One month following pamidronic acid therapy, the patient was hospitalised with hypocalcaemia. Author comment: "[O]ne case of osteonecrosis of the jaw was associated with extended administration of zoledronate for 27 months." "Although bisphosphonates have been shown to decrease the serum calcium level, limited data on longterm (>24 months) bisphosphonates-induced hypocalcaemia treatment was reported." Ding X, et al. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast 21: 544-549, No. 4, Aug 2012. Available from: URL: http:// 803438054 doi.org/10.1016/j.breast.2012.04.008 - China
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
